Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.48 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.44 |
| ▸ | DRD2 | P14416 | 1/20 | 0.42 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.42 |
| ▸ | SLC6A9 | P48067 | 1/20 | 0.42 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15499048 | 1.00 | HSD17B10 (0.48) | HSD17B10S1PR1DRD2SIGMAR1SLC6A9 | |
| SCHEMBL10060138 | 1.00 | HSD17B10 (0.48) | HSD17B10S1PR1DRD2SIGMAR1SLC6A9 | |
| SCHEMBL24177004 | 0.94 | HSD17B10 (0.44) | HSD17B10S1PR1DRD2SIGMAR1SLC6A9 | |
| SCHEMBL22434575 | 0.87 | MEN1 (0.40) | HSD17B10S1PR1DRD2SIGMAR1SLC6A9 | |
| SCHEMBL10060132 | 0.87 | HSD17B10 (0.39) | HSD17B10S1PR1DRD2SIGMAR1SLC6A9 | |
| SCHEMBL23105622 | 0.87 | S1PR1 (0.49) | HSD17B10S1PR1SMN1; SMN2CYP1A2MAPK1 | |
| SCHEMBL23646017 | 0.85 | HSD17B10 (0.62) | HSD17B10S1PR1SLC6A9SMN1; SMN2CYP1A2 | |
| SCHEMBL8742080 | 0.85 | HSD17B10 (0.62) | HSD17B10S1PR1SLC6A9SMN1; SMN2CYP1A2 | |
| SCHEMBL5848033 | 0.85 | S1PR1 (0.51) | HSD17B10S1PR1SMN1; SMN2CYP1A2MAPK1 | |
| SCHEMBL5548993 | 0.84 | S1PR1 (0.54) | S1PR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220135529-A1 | METAL/RADIOMETAL-LABELED PSMA INHIBITORS FOR PSMA-TARGETED IMAGING AND RADIOTHERAPY | THE JOHNS HOPKINS UNIVERSTY | 2022-05-05 | — | — | US | disclosed |
| US-20220105194-A1 | CONJUGATE COMPRISING LIGAND, SPACER, PEPTIDE LINKER, AND BIOMOLECULE | ASTELLAS PHARMA INC. (JP) | 2022-04-07 | — | — | US | disclosed |
| US-20200290982-A1 | METAL/RADIOMETAL-LABELED PSMA INHIBITORS FOR PSMA-TARGETED IMAGING AND RADIOTHERAPY | THE JOHNS HOPKINS UNIVERSTY | 2020-09-17 | — | — | US | disclosed |
| WO-2020160222-A2 | CONJUGATES OF BIVALENT EVANS BLUE DYE DERIVATIVES AND METHODS OF USE | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2020-08-06 | — | — | WO | disclosed |
| WO-2020145227-A1 | COMPLEX COMPRISING LIGAND, SPACER, PEPTIDE LINKER, AND BIOMOLECULE | アステラス製薬株式会社 | 2020-07-16 | — | — | WO | disclosed |
| WO-2020145228-A1 | COMPLEX COMPRISING LIGAND AND CEACAM5 ANTIBODY FAB FRAGMENT | アステラス製薬株式会社 | 2020-07-16 | — | — | WO | disclosed |
| WO-2019165200-A1 | CHEMICAL CONJUGATES OF EVANS BLUE DERIVATIVES AND THEIR USE AS RADIOTHERAPY AND IMAGING AGENTS FOR TARGETING PROSTATE CANCER | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2019-08-29 | — | — | WO | disclosed |
| WO-2019070236-A1 | CHEMICAL CONJUGATES OF EVANS BLUE DERIVATIVES AND THEIR USE AS RADIOTHERAPY AND IMAGING AGENTS | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2019-04-11 | — | — | WO | disclosed |
| US-20140065075-A1 | TARGETED CONTRAST AGENTS AND USES THEREOF | RF THERAPEUTICS INC. (CA) | 2014-03-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220105194-A1 | CONJUGATE COMPRISING LIGAND, SPACER, PEPTIDE LINKER, AND BIOMOLECULE | MUC1, CA14, CA13 | HSD17B10 4056/4885S1PR1 2791/4885DRD2 2945/4885 |
| US-20220135529-A1 | METAL/RADIOMETAL-LABELED PSMA INHIBITORS FOR PSMA-TARGETED IMAGING AND RADIOTHERAPY | PSMA6, PSMA1, UTS2R | HSD17B10 4846/4885S1PR1 2719/4885DRD2 4142/4885 |
| US-20140065075-A1 | TARGETED CONTRAST AGENTS AND USES THEREOF | ANTXR2, CALCOCO2, PAICS | HSD17B10 4822/4885S1PR1 2319/4885DRD2 3995/4885 |
| US-20200290982-A1 | METAL/RADIOMETAL-LABELED PSMA INHIBITORS FOR PSMA-TARGETED IMAGING AND RADIOTHERAPY | PSMA6, PSMA1, UTS2R | HSD17B10 4846/4885S1PR1 2719/4885DRD2 4142/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.